MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.290
0.000
0.00%
After Hours: 2.200 -0.09 -3.93% 19:48 09/24 EDT
OPEN
2.220
PREV CLOSE
2.290
HIGH
2.390
LOW
2.220
VOLUME
3.18M
TURNOVER
--
52 WEEK HIGH
4.400
52 WEEK LOW
1.780
MARKET CAP
118.02M
P/E (TTM)
-1.9506
1D
5D
1M
3M
1Y
5Y
GlycoMimetics' Lead Candidate Data Published In An Online Journal
Benzinga · 23h ago
BRIEF-Data For GlycoMimetics’ Lead Investigational Drug Uproleselan Published
reuters.com · 1d ago
Efficacy And Safety Data For GlycoMimetics' Lead Investigational Drug Uproleselan Published In BLOOD
Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists
Benzinga · 1d ago
Efficacy and Safety Data for GlycoMimetics' Lead Investigational Drug Uproleselan Published in BLOOD
Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists highlight an analysis of minimal residual diseas...
Business Wire · 1d ago
Are Institutions Heavily Invested In GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shares?
The big shareholder groups in GlycoMimetics, Inc. ( NASDAQ:GLYC ) have power over the company. Institutions often own...
Simply Wall St. · 09/10 12:10
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Harout Semerjian will present at the upcoming H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference taking place September 13-15, 2021. The presentation will be...
Business Wire · 09/08 13:00
MTCH, BILI and ZIOP among pre market gainers
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborat...
Seekingalpha · 09/07 12:22
Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
Zacks · 08/23 12:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLYC. Analyze the recent business situations of GlycoMimetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLYC stock price target is 10.67 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 117
Institutional Holdings: 46.05M
% Owned: 89.34%
Shares Outstanding: 51.54M
TypeInstitutionsShares
Increased
15
1.60M
New
9
571.53K
Decreased
22
5.36M
Sold Out
29
2.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Pearson
Chief Executive Officer
Harout Semerjian
Co-Founder/Senior Vice President/Chief Scientific Officer
John Magnani
Chief Financial Officer/Senior Vice President
Brian Hahn
Senior Vice President
Eric Feldman
Senior Vice President
Armand Girard
Director
Rachel King
Independent Director
Patricia Andrews
Independent Director
Mark Goldberg
Independent Director
Scott Jackson
Independent Director
Daniel Junius
Independent Director
Scott Koenig
No Data
  • All
  • Financials
  • Insiders
More
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.